<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03421197</url>
  </required_header>
  <id_info>
    <org_study_id>PPC-06-CD-004</org_study_id>
    <nct_id>NCT03421197</nct_id>
  </id_info>
  <brief_title>A Study to Assess the Efficacy and Safety of PPC-06 (Tepilamide Fumarate)</brief_title>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled, Multicenter, 24-Week Study to Assess the Efficacy and Safety of PPC-06 (Tepilamide Fumarate) Extended Release Tablets in Subjects With Moderate-to-Severe Plaque Psoriasis (AFFIRM)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dr. Reddy's Laboratories Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Dr. Reddy's Laboratories Limited</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, double-blind, placebo-controlled, multicenter study designed to assess&#xD;
      the safety and efficacy of PPC-06 (tepilamide fumarate) extended release in subjects with&#xD;
      moderate-to-severe plaque psoriasis.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase 2, randomized, double-blind, placebo-controlled, multicenter study designed&#xD;
      to assess the safety and efficacy of PPC-06 in subjects with moderate-to-severe plaque&#xD;
      psoriasis. Study subjects will be enrolled at approximately 75 sites in the United States&#xD;
      (US).&#xD;
&#xD;
      Approximately 400 subjects who meet the study entry criteria will be randomly assigned in a&#xD;
      1:1:1:1 ratio to 1 of the 4 treatment arms:&#xD;
&#xD;
        1. PPC-06 400 mg once daily (QD)&#xD;
&#xD;
        2. PPC-06 400 mg BID&#xD;
&#xD;
        3. PPC-06 600 mg BID&#xD;
&#xD;
        4. Placebo BID The maximum study duration for each subject will be approximately 29 weeks.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 25, 2018</start_date>
  <completion_date type="Actual">March 30, 2020</completion_date>
  <primary_completion_date type="Actual">March 30, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomized</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Achieving Psoriasis Area and Severity Index (PASI) - 75 at the End of Week 24</measure>
    <time_frame>End of Week 24</time_frame>
    <description>The percentage of subjects who achieve a reduction of 75% or greater from Baseline in the Psoriasis Area and Severity Index (PASI-75) The PASI is a measure of the average redness, thickness, and scaliness of the lesions (each graded on a 0-4 scale) and is weighted by the area of involvement. The minimum possible score on this scale is '0', while the maximum score on this scale is 72. A lower score on this scale at the end of the study indicates an improvement in the condition of subject.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Achieving the Investigator's Global Assessment (IGA) Score of 0 or 1</measure>
    <time_frame>End of Week 24</time_frame>
    <description>The Percentage of subjects who achieve the Investigator's Global Assessment (IGA) score of clear or almost clear (IGA score 0 or 1)&#xD;
Score Grade Definition 0 Clear: No signs of psoriasis&#xD;
Almost clear: No thickening to minimal plaque elevation; Normal to slight pink coloration/faint erythema; Focal to minimal scaling&#xD;
Mild: Slight elevation/thickening; Pink to light red coloration; Predominantly fine scaling partially or mostly covering lesions&#xD;
Moderate: Clearly distinguishable/distinct thickening; Definite red coloration; Coarse scaling covering most plaques&#xD;
Severe: Marked thickening with hard/sharp edges; Bright to deep dark red coloration; Thick/coarse scaling covering almost all or all lesions&#xD;
A lower score on this scale at the end of the study indicates an improvement in the disease condition.</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">426</enrollment>
  <condition>Psoriasis</condition>
  <arm_group>
    <arm_group_label>PPC-06 400 mg QD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tepilamide Fumarate 400 mg once per day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PPC-06 400 mg BID</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tepilamide Fumarate 400 mg twice per day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PPC-06 600 mg BID</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tepilamide Fumarate 600 mg twice per day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo BID</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>White placebo tablet to mimic Tepilamide Fumarate</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PPC-06 400 mg QD</intervention_name>
    <description>Tepilamide Fumarate 400 mg tablet once per day</description>
    <arm_group_label>PPC-06 400 mg QD</arm_group_label>
    <other_name>Tepilamide Fumarate 400 mg</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PPC-06 400 mg BID</intervention_name>
    <description>Tepilamide Fumarate tablets 400 mg twice per day</description>
    <arm_group_label>PPC-06 400 mg BID</arm_group_label>
    <other_name>Tepilamide Fumarate 400 mg</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PPC-06 600 mg</intervention_name>
    <description>Tepilamide Fumarate tablets 600 mg twice per day</description>
    <arm_group_label>PPC-06 600 mg BID</arm_group_label>
    <other_name>Tepilamide Fumarate 600 mg</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>white tablet with no active ingredient manufactured to mimic Tepilamide Fumarate tablets</description>
    <arm_group_label>Placebo BID</arm_group_label>
    <other_name>Placebo tablets twice per day</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Generally healthy males or non-pregnant females age ≥18 years at the time of screening&#xD;
             (or who have reached the state minimum legal age of consent).&#xD;
&#xD;
          -  Stable, moderate-to-severe plaque psoriasis diagnosed for at least 6 months prior to&#xD;
             randomization (no morphology changes or significant flares of disease activity in the&#xD;
             last 6 months in the opinion of the investigator or as reported by the subject).&#xD;
&#xD;
          -  Severity of disease meeting all 3 of the following criteria prior to randomization (at&#xD;
             the Baseline [Day 0] visit):&#xD;
&#xD;
               1. PASI score of ≥12&#xD;
&#xD;
               2. Total body surface area (BSA) affected by plaque psoriasis of ≥10%&#xD;
&#xD;
               3. IGA score of &gt;3&#xD;
&#xD;
          -  Must be a candidate for phototherapy and/or systemic therapy for psoriasis.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subjects with non-plaque psoriasis (ie, predominantly inverse, erythrodermic,&#xD;
             predominantly guttate, or pustular psoriasis).&#xD;
&#xD;
          -  Subjects with drug-induced psoriasis or subjects with drug-exacerbated psoriasis that&#xD;
             has not resolved within 4 weeks prior to screening.&#xD;
&#xD;
          -  Subjects who have received systemic non-biologic psoriasis therapy or phototherapy&#xD;
             (including either oral and topical psoralen and ultraviolet A (PUVA) light therapy,&#xD;
             ultraviolet B, or self-treatment with tanning beds or therapeutic sunbathing) within 4&#xD;
             weeks prior to the Baseline Visit.&#xD;
&#xD;
          -  Subjects who had topical psoriasis treatment within the previous 2 weeks prior to the&#xD;
             Baseline Visit.&#xD;
&#xD;
          -  Subjects with history of concurrent or recent use of any biologic agent within the&#xD;
             following washout periods prior to baseline visit:&#xD;
&#xD;
               -  Etanercept - 35 days&#xD;
&#xD;
               -  Infliximab, adalimumab - 12 weeks&#xD;
&#xD;
               -  Ustekinumab - 24 weeks&#xD;
&#xD;
               -  Any other biologic agent &lt;5 half-lives prior to the Baseline Visit&#xD;
&#xD;
          -  Subjects with history of use of any investigational drug within 28 days prior to&#xD;
             randomization, or 5 pharmacokinetic/ pharmacodynamic half-lives (whichever is longer).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Srinivas Sidgiddi, MD</last_name>
    <role>Study Director</role>
    <affiliation>Dr. Reddy's Laboratories, Inc</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Site 144</name>
      <address>
        <city>Glendale</city>
        <state>Arizona</state>
        <zip>85308</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 167</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85018</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 158</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85053</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 170</name>
      <address>
        <city>Tempe</city>
        <state>Arizona</state>
        <zip>85283</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 157</name>
      <address>
        <city>Bryant</city>
        <state>Arkansas</state>
        <zip>72022</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 125</name>
      <address>
        <city>Rogers</city>
        <state>Arkansas</state>
        <zip>72758</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 133</name>
      <address>
        <city>Fountain Valley</city>
        <state>California</state>
        <zip>92708</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 107</name>
      <address>
        <city>Fremont</city>
        <state>California</state>
        <zip>94538</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 121</name>
      <address>
        <city>Fresno</city>
        <state>California</state>
        <zip>93720</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 153</name>
      <address>
        <city>Fullerton</city>
        <state>California</state>
        <zip>92835</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 176</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90057</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 178</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90057</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 182</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90057</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 156</name>
      <address>
        <city>Murrieta</city>
        <state>California</state>
        <zip>92562</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 141</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92123</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 155</name>
      <address>
        <city>Santa Rosa</city>
        <state>California</state>
        <zip>95405</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 137</name>
      <address>
        <city>Clearwater</city>
        <state>Florida</state>
        <zip>33761</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 130</name>
      <address>
        <city>Coral Gables</city>
        <state>Florida</state>
        <zip>33134</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 143</name>
      <address>
        <city>Hialeah</city>
        <state>Florida</state>
        <zip>33012</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 145</name>
      <address>
        <city>Hialeah</city>
        <state>Florida</state>
        <zip>33012</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 181</name>
      <address>
        <city>Hialeah</city>
        <state>Florida</state>
        <zip>33012</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 149</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33014</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 105</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33144</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 174</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33155</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 164</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33175</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 123</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33186</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 112</name>
      <address>
        <city>Miramar</city>
        <state>Florida</state>
        <zip>33027</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 172</name>
      <address>
        <city>New Port Richey</city>
        <state>Florida</state>
        <zip>34655</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 152</name>
      <address>
        <city>Orange Park</city>
        <state>Florida</state>
        <zip>32073</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 154</name>
      <address>
        <city>Pembroke Pines</city>
        <state>Florida</state>
        <zip>33028</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 110</name>
      <address>
        <city>Sweetwater</city>
        <state>Florida</state>
        <zip>33172</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 150</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33609</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 113</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33624</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 132</name>
      <address>
        <city>Marietta</city>
        <state>Georgia</state>
        <zip>30060</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 124</name>
      <address>
        <city>Savannah</city>
        <state>Georgia</state>
        <zip>31406</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 122</name>
      <address>
        <city>Nampa</city>
        <state>Idaho</state>
        <zip>83651</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 179</name>
      <address>
        <city>Wheaton</city>
        <state>Illinois</state>
        <zip>60189</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 115</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46256</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 171</name>
      <address>
        <city>New Albany</city>
        <state>Indiana</state>
        <zip>47150</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 139</name>
      <address>
        <city>Overland Park</city>
        <state>Kansas</state>
        <zip>66215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 165</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 131</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40217</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 142</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40241</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 119</name>
      <address>
        <city>Baton Rouge</city>
        <state>Louisiana</state>
        <zip>70808</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 126</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 128</name>
      <address>
        <city>Clinton Township</city>
        <state>Michigan</state>
        <zip>48038</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 129</name>
      <address>
        <city>Fridley</city>
        <state>Minnesota</state>
        <zip>55432</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 111</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 109</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 127</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89119</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 180-</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89148</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 103</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10012</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 177</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10075</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 104</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10155</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 161</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14623</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 146</name>
      <address>
        <city>Stony Brook</city>
        <state>New York</state>
        <zip>11790</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 108</name>
      <address>
        <city>High Point</city>
        <state>North Carolina</state>
        <zip>27262</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 116</name>
      <address>
        <city>Wilmington</city>
        <state>North Carolina</state>
        <zip>28405</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 118</name>
      <address>
        <city>Beachwood</city>
        <state>Ohio</state>
        <zip>44122</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 169</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45236</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 114</name>
      <address>
        <city>Johnston</city>
        <state>Rhode Island</state>
        <zip>02919</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 134</name>
      <address>
        <city>Mount Pleasant</city>
        <state>South Carolina</state>
        <zip>29464</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 100</name>
      <address>
        <city>Rapid City</city>
        <state>South Dakota</state>
        <zip>57702</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 148</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78745</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 160</name>
      <address>
        <city>Bellaire</city>
        <state>Texas</state>
        <zip>77401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 162</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77004</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 102</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77056</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 106</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 101</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78281</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 159</name>
      <address>
        <city>Sugar Land</city>
        <state>Texas</state>
        <zip>77479</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 136</name>
      <address>
        <city>Orem</city>
        <state>Utah</state>
        <zip>84058</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 166</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23507</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 135</name>
      <address>
        <city>Burien</city>
        <state>Washington</state>
        <zip>98168</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 147</name>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <zip>99202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>January 23, 2018</study_first_submitted>
  <study_first_submitted_qc>January 29, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">February 5, 2018</study_first_posted>
  <results_first_submitted>February 26, 2021</results_first_submitted>
  <results_first_submitted_qc>April 17, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">May 11, 2021</results_first_posted>
  <last_update_submitted>April 17, 2021</last_update_submitted>
  <last_update_submitted_qc>April 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psoriasis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>October 26, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/97/NCT03421197/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>April 15, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/97/NCT03421197/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>PPC-06 400 mg QD</title>
          <description>Tepilamide Fumarate 400 mg once per day&#xD;
PPC-06 400 mg QD: Tepilamide Fumarate 400 mg tablet once per day</description>
        </group>
        <group group_id="P2">
          <title>PPC-06 400 mg BID</title>
          <description>Tepilamide Fumarate 400 mg twice per day&#xD;
PPC-06 400 mg BID: Tepilamide Fumarate tablets 400 mg twice per day</description>
        </group>
        <group group_id="P3">
          <title>PPC-06 600 mg BID</title>
          <description>Tepilamide Fumarate 600 mg twice per day&#xD;
PPC-06 600 mg: Tepilamide Fumarate tablets 600 mg twice per day</description>
        </group>
        <group group_id="P4">
          <title>Placebo BID</title>
          <description>White placebo tablet to mimic Tepilamide Fumarate&#xD;
Placebo: white tablet with no active ingredient manufactured to mimic Tepilamide Fumarate tablets</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="105"/>
                <participants group_id="P2" count="107"/>
                <participants group_id="P3" count="107"/>
                <participants group_id="P4" count="107"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="67"/>
                <participants group_id="P2" count="68"/>
                <participants group_id="P3" count="56"/>
                <participants group_id="P4" count="62"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="38"/>
                <participants group_id="P2" count="39"/>
                <participants group_id="P3" count="51"/>
                <participants group_id="P4" count="45"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>PPC-06 400 mg QD</title>
          <description>Tepilamide Fumarate 400 mg once per day&#xD;
PPC-06 400 mg QD: Tepilamide Fumarate 400 mg tablet once per day</description>
        </group>
        <group group_id="B2">
          <title>PPC-06 400 mg BID</title>
          <description>Tepilamide Fumarate 400 mg twice per day&#xD;
PPC-06 400 mg BID: Tepilamide Fumarate tablets 400 mg twice per day</description>
        </group>
        <group group_id="B3">
          <title>PPC-06 600 mg BID</title>
          <description>Tepilamide Fumarate 600 mg twice per day&#xD;
PPC-06 600 mg: Tepilamide Fumarate tablets 600 mg twice per day</description>
        </group>
        <group group_id="B4">
          <title>Placebo BID</title>
          <description>White placebo tablet to mimic Tepilamide Fumarate&#xD;
Placebo: white tablet with no active ingredient manufactured to mimic Tepilamide Fumarate tablets</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="105"/>
            <count group_id="B2" value="107"/>
            <count group_id="B3" value="107"/>
            <count group_id="B4" value="107"/>
            <count group_id="B5" value="426"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="48.0" spread="13.18"/>
                    <measurement group_id="B2" value="51.0" spread="12.29"/>
                    <measurement group_id="B3" value="50.2" spread="13.74"/>
                    <measurement group_id="B4" value="49.3" spread="12.59"/>
                    <measurement group_id="B5" value="49.6" spread="12.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                    <measurement group_id="B2" value="43"/>
                    <measurement group_id="B3" value="43"/>
                    <measurement group_id="B4" value="43"/>
                    <measurement group_id="B5" value="169"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="65"/>
                    <measurement group_id="B2" value="64"/>
                    <measurement group_id="B3" value="64"/>
                    <measurement group_id="B4" value="64"/>
                    <measurement group_id="B5" value="257"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="11"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="26"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="97"/>
                    <measurement group_id="B2" value="96"/>
                    <measurement group_id="B3" value="92"/>
                    <measurement group_id="B4" value="97"/>
                    <measurement group_id="B5" value="382"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="105"/>
                    <measurement group_id="B2" value="107"/>
                    <measurement group_id="B3" value="107"/>
                    <measurement group_id="B4" value="107"/>
                    <measurement group_id="B5" value="426"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Psoriasis Area and Severity Index (PASI)</title>
          <description>The PASI is a measure of the average redness, thickness, and scaliness of the lesions (each graded on a 0-4 scale) and is weighted by the area of involvement. The three signs are assessed on 4 body regions - Head, Trunk, Upper Limbs and Lower Limbs. Scores for each sign are assigned on all body regions and calculated per a validated formula. The minimum possible score is 0, while maximum score on this scale is 72. A lower score on this scale at the end of the study indicates an improvement in the condition of the subject.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18.41" spread="6.377"/>
                    <measurement group_id="B2" value="18.56" spread="8.004"/>
                    <measurement group_id="B3" value="18.00" spread="6.680"/>
                    <measurement group_id="B4" value="17.26" spread="6.169"/>
                    <measurement group_id="B5" value="18.05" spread="6.842"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Achieving Psoriasis Area and Severity Index (PASI) - 75 at the End of Week 24</title>
        <description>The percentage of subjects who achieve a reduction of 75% or greater from Baseline in the Psoriasis Area and Severity Index (PASI-75) The PASI is a measure of the average redness, thickness, and scaliness of the lesions (each graded on a 0-4 scale) and is weighted by the area of involvement. The minimum possible score on this scale is '0', while the maximum score on this scale is 72. A lower score on this scale at the end of the study indicates an improvement in the condition of subject.</description>
        <time_frame>End of Week 24</time_frame>
        <population>Full Analysis Set (FAS) Population which included all randomized subjects who received at least one dose of IP and had at least one post-dose efficacy assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>PPC-06 400 mg QD</title>
            <description>Tepilamide Fumarate 400 mg once per day&#xD;
PPC-06 400 mg QD: Tepilamide Fumarate 400 mg tablet once per day</description>
          </group>
          <group group_id="O2">
            <title>PPC-06 400 mg BID</title>
            <description>Tepilamide Fumarate 400 mg twice per day&#xD;
PPC-06 400 mg BID: Tepilamide Fumarate tablets 400 mg twice per day</description>
          </group>
          <group group_id="O3">
            <title>PPC-06 600 mg BID</title>
            <description>Tepilamide Fumarate 600 mg twice per day&#xD;
PPC-06 600 mg: Tepilamide Fumarate tablets 600 mg twice per day</description>
          </group>
          <group group_id="O4">
            <title>Placebo BID</title>
            <description>White placebo tablet to mimic Tepilamide Fumarate&#xD;
Placebo: white tablet with no active ingredient manufactured to mimic Tepilamide Fumarate tablets</description>
          </group>
        </group_list>
        <measure>
          <title>Achieving Psoriasis Area and Severity Index (PASI) - 75 at the End of Week 24</title>
          <description>The percentage of subjects who achieve a reduction of 75% or greater from Baseline in the Psoriasis Area and Severity Index (PASI-75) The PASI is a measure of the average redness, thickness, and scaliness of the lesions (each graded on a 0-4 scale) and is weighted by the area of involvement. The minimum possible score on this scale is '0', while the maximum score on this scale is 72. A lower score on this scale at the end of the study indicates an improvement in the condition of subject.</description>
          <population>Full Analysis Set (FAS) Population which included all randomized subjects who received at least one dose of IP and had at least one post-dose efficacy assessment.</population>
          <units>percentage of total participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="101"/>
                <count group_id="O2" value="102"/>
                <count group_id="O3" value="101"/>
                <count group_id="O4" value="102"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39.7"/>
                    <measurement group_id="O2" value="47.2"/>
                    <measurement group_id="O3" value="44.3"/>
                    <measurement group_id="O4" value="20.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Achieving the Investigator's Global Assessment (IGA) Score of 0 or 1</title>
        <description>The Percentage of subjects who achieve the Investigator's Global Assessment (IGA) score of clear or almost clear (IGA score 0 or 1)&#xD;
Score Grade Definition 0 Clear: No signs of psoriasis&#xD;
Almost clear: No thickening to minimal plaque elevation; Normal to slight pink coloration/faint erythema; Focal to minimal scaling&#xD;
Mild: Slight elevation/thickening; Pink to light red coloration; Predominantly fine scaling partially or mostly covering lesions&#xD;
Moderate: Clearly distinguishable/distinct thickening; Definite red coloration; Coarse scaling covering most plaques&#xD;
Severe: Marked thickening with hard/sharp edges; Bright to deep dark red coloration; Thick/coarse scaling covering almost all or all lesions&#xD;
A lower score on this scale at the end of the study indicates an improvement in the disease condition.</description>
        <time_frame>End of Week 24</time_frame>
        <population>Full Analysis Set (FAS) Population included all randomized subjects who received at least one dose of IP and had at least one post-dose efficacy assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>PPC-06 400 mg QD</title>
            <description>Tepilamide Fumarate 400 mg once per day&#xD;
PPC-06 400 mg QD: Tepilamide Fumarate 400 mg tablet once per day</description>
          </group>
          <group group_id="O2">
            <title>PPC-06 400 mg BID</title>
            <description>Tepilamide Fumarate 400 mg twice per day&#xD;
PPC-06 400 mg BID: Tepilamide Fumarate tablets 400 mg twice per day</description>
          </group>
          <group group_id="O3">
            <title>PPC-06 600 mg BID</title>
            <description>Tepilamide Fumarate 600 mg twice per day&#xD;
PPC-06 600 mg: Tepilamide Fumarate tablets 600 mg twice per day</description>
          </group>
          <group group_id="O4">
            <title>Placebo BID</title>
            <description>White placebo tablet to mimic Tepilamide Fumarate&#xD;
Placebo: white tablet with no active ingredient manufactured to mimic Tepilamide Fumarate tablets</description>
          </group>
        </group_list>
        <measure>
          <title>Achieving the Investigator's Global Assessment (IGA) Score of 0 or 1</title>
          <description>The Percentage of subjects who achieve the Investigator's Global Assessment (IGA) score of clear or almost clear (IGA score 0 or 1)&#xD;
Score Grade Definition 0 Clear: No signs of psoriasis&#xD;
Almost clear: No thickening to minimal plaque elevation; Normal to slight pink coloration/faint erythema; Focal to minimal scaling&#xD;
Mild: Slight elevation/thickening; Pink to light red coloration; Predominantly fine scaling partially or mostly covering lesions&#xD;
Moderate: Clearly distinguishable/distinct thickening; Definite red coloration; Coarse scaling covering most plaques&#xD;
Severe: Marked thickening with hard/sharp edges; Bright to deep dark red coloration; Thick/coarse scaling covering almost all or all lesions&#xD;
A lower score on this scale at the end of the study indicates an improvement in the disease condition.</description>
          <population>Full Analysis Set (FAS) Population included all randomized subjects who received at least one dose of IP and had at least one post-dose efficacy assessment.</population>
          <units>percentage of total participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="101"/>
                <count group_id="O2" value="102"/>
                <count group_id="O3" value="101"/>
                <count group_id="O4" value="102"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.7"/>
                    <measurement group_id="O2" value="41.4"/>
                    <measurement group_id="O3" value="44.4"/>
                    <measurement group_id="O4" value="22.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were collected from the time of signing the informed consent, up to 30 days after the last dose.</time_frame>
      <desc>Adverse events were assessed at all study visits. Adverse events were monitored by the investigator from the time of signing informed consent, up to 30 days after the subject has stopped study treatment or until the AE had resolved or stabilized.&#xD;
Adverse events were evaluated in the Safety Population.</desc>
      <group_list>
        <group group_id="E1">
          <title>PPC-06 400 mg QD</title>
          <description>Tepilamide Fumarate 400 mg once per day&#xD;
PPC-06 400 mg QD: Tepilamide Fumarate 400 mg tablet once per day</description>
        </group>
        <group group_id="E2">
          <title>PPC-06 400 mg BID</title>
          <description>Tepilamide Fumarate 400 mg twice per day&#xD;
PPC-06 400 mg BID: Tepilamide Fumarate tablets 400 mg twice per day</description>
        </group>
        <group group_id="E3">
          <title>PPC-06 600 mg BID</title>
          <description>Tepilamide Fumarate 600 mg twice per day&#xD;
PPC-06 600 mg: Tepilamide Fumarate tablets 600 mg twice per day</description>
        </group>
        <group group_id="E4">
          <title>Placebo BID</title>
          <description>White placebo tablet to mimic Tepilamide Fumarate&#xD;
Placebo: white tablet with no active ingredient manufactured to mimic Tepilamide Fumarate tablets</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 20.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="105"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="107"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="107"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="105"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="107"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Hypersensitivity</sub_title>
                <description>Allergic Reaction</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="107"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="107"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="105"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title vocab="MedDra 20.0">Staphylococcal skin infection</sub_title>
                <description>Staphylococcal skin infection in right lower leg</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="107"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Femur fracture</sub_title>
                <description>Right femur</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="107"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="107"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="107"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="107"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cervical cord compression</sub_title>
                <description>C-Spine Compression</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="107"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title vocab="MedDra 20.0">Dyspnoea/Shortness of Breath</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="105"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="107"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDra 20.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="105"/>
                <counts group_id="E2" subjects_affected="42" subjects_at_risk="107"/>
                <counts group_id="E3" subjects_affected="68" subjects_at_risk="106"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="107"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Lymphopenia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="105"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="107"/>
                <counts group_id="E3" events="10" subjects_affected="10" subjects_at_risk="106"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title vocab="MedDRA 20.0">Eosinophilia</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="105"/>
                <counts group_id="E2" events="7" subjects_affected="6" subjects_at_risk="107"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="106"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="107"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="12" subjects_affected="7" subjects_at_risk="105"/>
                <counts group_id="E2" events="20" subjects_affected="19" subjects_at_risk="107"/>
                <counts group_id="E3" events="32" subjects_affected="24" subjects_at_risk="106"/>
                <counts group_id="E4" events="5" subjects_affected="5" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="8" subjects_affected="7" subjects_at_risk="105"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="107"/>
                <counts group_id="E3" events="11" subjects_affected="11" subjects_at_risk="106"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Abdominal Pain</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="105"/>
                <counts group_id="E2" events="6" subjects_affected="5" subjects_at_risk="107"/>
                <counts group_id="E3" events="13" subjects_affected="12" subjects_at_risk="106"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="107"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title vocab="MedDRA 20.0">Urinary Tract Infection</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="105"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="107"/>
                <counts group_id="E3" events="7" subjects_affected="6" subjects_at_risk="106"/>
                <counts group_id="E4" events="3" subjects_affected="2" subjects_at_risk="107"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Srinivas Sidgiddi, Sr Director, Clinical Development</name_or_title>
      <organization>Dr Reddy's Laboratories</organization>
      <phone>609-375-9910</phone>
      <email>srinivassidgiddi@drreddys.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

